The current financial score of Atea Pharmaceuticals Inc is 6.09. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Atea Pharmaceuticals Inc is 7.96. Its current P/E ratio is -2.51, which is -43.66% below the recent high of -1.41 and -53.56% above the recent low of -3.86.
The current earnings forecast score of Atea Pharmaceuticals Inc is 8.00. The average price target is 8.50, with a high of 10.00 and a low of 7.00.
The current price momentum score of Atea Pharmaceuticals Inc is 3.63. Currently, the stock price is trading between the resistance level at 5.81 and the support level at 4.90, making it suitable for range-bound swing trading.
The current institutional shareholding score of Atea Pharmaceuticals Inc is 7.00. The latest institutional shareholding proportion is 70.93%, representing a quarter-over-quarter decrease of 6.89%. The largest institutional shareholder is James Simons, holding a total of 1.13M shares, representing 0.01% of shares outstanding, with 25.22% increase in holdings.
The current risk assessment score of Atea Pharmaceuticals Inc is 5.17. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.